falsefalse

ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 6

Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

, , , ,

Experts discuss a preference for ipilimumab/nivolumab as the frontline immunotherapy for patients with BRAF-mutant metastatic melanoma given its proven long-term efficacy but acknowledge nivolumab/relatlimab as an option with less toxicity, especially adrenal insufficiency.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Role of Biomarker Testing in the Management of Metastatic Melanoma
    EP. 2: Best Practices for Biomarker Testing in Metastatic Melanoma
    EP. 3: Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma
    EP. 4: Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation
    EP. 5: Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma
    Now Viewing
    EP. 6: Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma
    EP. 7: Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma
    EP. 8: Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma
    EP. 9: Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial
    EP. 10: Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma
    EP. 11: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases
    EP. 12: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases
    EP. 13: Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases
    EP. 14: The Future of Metastatic and Unresectable Melanoma Treatment

    Related Content:

    ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of MelanomaMelanoma & Skin CancerOncLive Peer Exchange®
    Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM
    Application of Real-World Evidence in Selecting CAR T in R/R MM
    Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC
    x